suggest that together with KIR2DL2, activating KIR2DS1 and KIR2DS2 expression limits KIR2DL1 acquisition on NK cells. Altogether, our results suggest that the NK cell repertoire is remolded by the activating and inhibitory KIR2D and their cognate ligands. The Journal of Immunology, 2013, 191: 000-000. N atural killer cells constitute the first line of defense against viral infections and tumor cells. These effectors of innate immunity discriminate self and nonself via inhibitory receptors that recognize HLA class I molecules in an allelic fashion. The absence or default of HLA class I expression on altered cells is a well-established characteristic of virally transformed and tumor cells, and leads to enhanced NK cell proliferation, cytotoxicity, and cytokine production (1) . These functional abilities confer to alloreactive NK cells a preponderant contribution to cell responses in allogeneic hematopoietic stem cell transplantation (HSCT) (2, 3) . Similarly, a semiallogeneic context observed in pregnancy constitutes a new HLA environment that requires a complete modulation of self HLA molecules to avoid activation of NK cells via inhibitory receptors. Among inhibitory receptors, killer Ig-like receptors (KIRs) recognize mainly HLA-C molecules. The nonclassical HLA-E molecule presents a peptide from the signal peptide of HLA class I molecules and constitutes a second line of self-presentation. This molecule is recognized by the inhibitory heterodimer CD94/NKG2A, which is acquired before KIRs on NK cells during development (4) . Finally, ILT-2 recognizes all HLA class I molecules by engaging the conserved b2-microglobulin and a3 domain of HLA class I molecules. KIRs are clonally expressed (5) on NK cells, leading to large combinations of KIR expression in different proportions of each KIR NK cell subset (6) . During development, NK cells acquire a functional potential that is, in part, determined by the capacities of each NK cell to engage its inhibitory receptors with self HLA class I molecules (7) . In addition, the number of KIR gene copies contributes to increased NK cell responsiveness (8) . Different theories have been proposed to explain the formation of the KIR NK cell repertoire. Some groups have proposed a model following a sequential acquisition of KIR that is dependent on the HLA environment (9) . In parallel, based on combinatorial analysis of KIR NK cells from haplotype AA individuals, Malmberg's group (10) has proposed that the variegated repertoires are generated through sequential and random acquisition of KIRs in a manner that is independent of the presence or absence of cognate HLA class I molecules. Thus, the impact of self HLA class I molecules on the frequency of all KIR NK subsets is still debated. Even though NK receptor-specific genes are not located in chromosome 6 like the HLA gene complex, the HLA environment appears nevertheless an important determinant to the formation and function of the NK cell repertoire.
The KIR gene family comprises 16 genes and is located on chromosome 19. KIR2DL1, KIR2DL2, and KIR2DL3 recognize HLA-C molecules depending on the nature of amino acid at position 80 and leads to two groups of ligands: C1 (Asn 80 ) and C2 (Lys 80 ). Thus, KIR2DL1 recognizes HLA-C molecules of C2 group, and KIR2DL2 and KIR2DL3, which are allelic genes, recognize HLA-C molecules of C1group (11) . KIR2DL2 presents a weaker affinity to C2 ligand (12) with the N77K80 motif (13) . Activating KIR specificity is less well documented even though KIR2DS1 recognizes HLA-C of group C2 as its inhibitory counterpart (14, 15) . KIR2DS3 is not expressed at the cell surface (16) , and its function is questionable especially because the gene is missing from some populations such as the Yucpa group studied by Parham's group (17) . If the alloreactive rules of C2 specific KIR2DS1 + NK cells are well understood, those involving KIR2DS2 are less documented. This is largely explained by the absence of Abs distinguishing the activating KIR2DS2 and inhibitory KIR2DL2 forms. Studies to date have mainly relied on the use of Abs specific for KIR2DL2/3 and KIR2DS2 as the GL183, which does not allow differentiation between inhibitory and activating forms. This may induce a possible bias in the interpretation of results involving two functional receptors with opposite signals but sharing potentially the same ligands, most likely because of the high homology of the extracellular portion of KIR2DL2 and KIR2DS2. Thus, we dissected the main inhibitory KIR2DL1/2/3 and activating KIR2DS1/2 reactivity from primary NK cells from HLA and KIR genotyped individuals. Our experimental approach has been validated in studying alloreactive KIR2DL1 and KIR2DS1 NK cell subsets against a wide range of target cell lines expressing different HLA-C ligands from C1 and C2 groups. Taking into account all revisited specificities of the main inhibitory KIR2DL1/2/3, activating KIR2DS1/2 and the alloreactive rules, we analyzed phenotypically the KIR NK cell repertoire from a large cohort of 159 KIR and HLA genotyped individuals to evaluate the influence of KIR ligand expression on NK cell repertoire formation.
Materials and Methods

Cells (PBMCs and cell lines)
PBMCs were isolated as previously described (15, 18) . All blood donors were recruited at the Blood Transfusion Center (Etablissement Français du Sang, Nantes, France), and informed consent was given by all donors. HLA class I-deficient 721.221 lymphoblastoid cells, referred to as 221 cells, were used as positive control to assess NK cell degranulation. HLA-C*03:04 (C1), HLA-C*08:02 (C1), HLA-C*04:01 (C2), HLA-C*02:02 (C2), HLA-C*06:02 (C2), HLA-C*07:01 (C1), and HLA-C*15:01 (C2) transfected 221 cells were used to evaluate NK cell degranulation of different KIR2D NK cell subsets. HLA-C*02:02, HLA-C*03:04, HLA-C*04:03, and HLA-C*07:01 transfected 221 cells were provided by Prof. P. Parham. HLA-C*08:02, HLA-C*02:02, HLA-C*06:02, and HLA-C*15:01 transfected 221 cells were obtained by stable transfection of 221 cell line by electroporation (BioRad) using, respectively, pcINeo-HLA-C*08:02 (provided by Dr. Agnès Moreau, INSERM Unite Mixte de Recherche 892, Nantes, France), pcINeo-HLA-C*06:02 (provided by Dr. Agnès Moreau, INSERM Unite Mixte de Recherche 892), and HLA-C*15:01 (provided by Dr. Frédérique Triebel, Immutep S.A., ChatenayMalabry, France). All HLA-C cDNA encoded sequences were verified by DNA sequencing as described: HLA-C polymorphic exons were amplified using the HLA-C.exon 1.68G (59-GGCCCTGACCGAGACCTG-39) forward primer and the HLA-C.exon 4.661C (59-CCTCAGGGTGGCCT-CATG-39) reverse primer. Amplification of exons 2 and 3 of the HLA-C locus was performed in 50 ml using 80 ng DNA, 0.2 mM dNTP (Invitrogen), 1 U Taq Gold polymerase (Applied Biosystems), 13 Taq Gold buffer (Applied), 2.5 mM MgCl 2 Gold (Applied), and 1 mM of each primer. Amplification presequencing was performed in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystem). The PCR amplification program included one denaturation step of 95˚C for 10 min, 36 cycles of 96˚C for 20 s, 60˚C for 30 s, and 72˚C for 3 min, followed by a final elongation step of 72˚C for 10 min. Products were electrophoresed on 2% agarose gels. HLA-C cDNA sequencing was performed by the Sequencing Core Facility (SFR François Bonamy, Nantes, France) using an ABI 3730 automatic system (Applied). HLA-C cDNA sequence data files were analyzed using Assign software (Conexio Genomics, Applecross, Australia) with IPD-HLA database version 3.9.0 (July 2012). The 221 cell line and HLA-C-transfected 221 cell lines were cultured in RPMI 1640 medium (Life Technologies, Paisley, U.K.) containing glutamine (Life Technologies) and penicillin-streptomycin (Life Technologies), and supplemented with 10% FBS (Life Technologies). Mycoplasma tests performed by PCR were negative for all cell lines.
HLA and KIR genotyping
HLA class I allele assignment and KIR gene content typing were performed as previously described (15, 18) . KIR haplotypes were determined as previously described (6) . The A haplotypes correspond to seven KIR genes, including KIR2DS4 as the only activating KIR gene. In contrast, B haplotypes are characterized by the presence of more than one activating KIR gene and the absence of the KIR2DS4 gene.
KIR NK cell line and clone isolation and amplification
PBMCs were stained with anti-CD3 mAb (X35, a gift from Dr. Franck Vérité, Etablissement Français du Sang, Rennes), and CD3 + cells were depleted using murine IgG coupled magnetic Dynabeads according to the manufacturer's instructions (Dynal, Oslo, Norway). Then cells were labeled with appropriate mAb combinations, and the cells were sorted using a FACSCalibur equipped with a fluidic sort module (BD Biosciences). Sorted cells were amplified after in vitro stimulation with irradiated allogeneic PBMCs and HLA-C*03:04 (C1) and HLA-C*04:01 (C2) transfected 221 cell lines used as feeders following the PBMC/EBV-B cells ratio at 10:1. KIR2DS2 + NK cells were cloned at 0.3 cell/well from the selected and amplified lines under limiting conditions in 96-well U-bottom microtiter plates with 50,000 irradiated autologous lymphocytes and 5000 irradiated HLA-C*03:04 (C1) and HLA-C*04:01 (C2) transfected 221 cell lines in a final volume of 100 ml. Growing colonies with a probability of monoclonality of 95% were kept for further analysis. NK cell lines and clones were cultured in RPMI 1640 medium (Life Technologies, Paisley, U.K.) containing glutamine (Life Technologies) and penicillin-streptomycin (Life Technologies), and supplemented with 10% human serum (Etablissement Français du Sang, Nantes, France) and 200 U/ml IL-2 (Chiron, Suresnes, France). Cells were maintained for 3 wk and expanded in their culture medium containing IL-2 without restimulation with feeders before functional analysis to decrease their spontaneous degranulation.
KIR2DL2 RT-PCR
Total RNA was purified from isolated KIR2DS2 + NK clones using NucleoSpin RNAXS (Macherey-Nagel). Qualitative KIR2DL2 RT-PCR was performed using a One-Step PrimeScript RT-PCR kit (TaKaRa, Japan) with KIR2DL2-specific primers from Thompson et al. (19) .
Phenotypic analysis by flow cytometry
The NK cell-surface phenotype was determined by three-or four-color flow cytometry using the following mouse anti-human mAbs: anti-KIR2DL1-FITC (143211; R&D Systems), anti-KIR2DL1/2DS1-PE (EB6), anti-KIR2DL2/2DS2-PE (GL183; Beckman Coulter Immunotech, Marseille, France), anti-CD3-PerCP (SK7), anti-CD56-allophycocyanin (B159; BD Biosciences), anti-KIR2DL1/2/3/2DS2-FITC (8C11), anti-KIR2DL3/2DS2 (1F12), and anti-KIR2DL1/2/3/2DS1/2-FITC (1A6), generated and characterized in our laboratory and previously described (20) . The KIR2DS2 + NK cell clone phenotype was determined using the following mouse anti-human mAbs: anti-KIR2DS4 (FES172; Beckman Coulter), anti-KIR3DL1/3DS1 (Z27; Beckman Coulter), anti-NKp30 (Z25; Beckman Coulter) anti-NKp44 (Z231; Beckman Coulter), anti-NKG2D (ID11; BD Biosciences), anti-2B4 (2-69; BD Biosciences), anti-ILT2 (GHI/75; BD Biosciences), anti-NKG2A (Z199; Beckman Coulter), and anti-CD16 (NKP15; BD Biosciences).
CD107a mobilization assay detected by flow cytometry
NK cells were preincubated with anti-CD107a (H4A3; BD Biosciences). NK cell degranulation was assessed after incubation for 5 h alone (negative control), or with different target cells (E:T ratio = 10:1) with brefeldin A (Sigma) at 10 mg/ml for the last 4 h. Cell-surface staining was performed using the anti-human KIR mAbs mentioned in the previous section and NKG2A-FITC or -PE (Z199; Beckman Coulter). All flow cytometry data were collected using a FACSCalibur (BD Biosciences) and analyzed using FlowJo 7.6.1 software (TreeStar).
Statistical analyses
Comparisons of NK cell frequencies between two different series of individuals were performed using ANOVA test. The p values , 0.05 were considered to be statistically significant. Top and bottom whiskers represent values of the top and bottom 25% of cases, respectively; boxed area represents interquartile range.
Results
C1
2 activated KIR2DL2 + and KIR2DL3 + NK cells present a similar degranulation potential to their C1 + counterparts
As a first step, we studied degranulation of KIR2DL NK subpopulations expressing either KIR2DL1, KIR2DL2, or KIR2DL3 using appropriate combinations of KIR-specific Abs targeting each of these receptors as previously described (20) (Fig. 1A) . Thus, KIR2DL1 + KIR2DL2/3/S1/2 2 NK cells were sorted using a combination of KIR2DL1/2/3/S2-specific 8C11 and KIR2DL2/3/ S2-specific GL183 Abs from KIR2DS1 2 genotyped individuals ( Fig. 1A ). KIR2DL2 + KIR2DL1/3/S1/2 2 NK cells were sorted using a combination of a mix of KIR2DL3/S2-specific 1F12 with KIR2DL1-specific 143211 Abs and KIR2DL2/3/S2-specific GL183 from KIR2DS1 2 genotyped individuals (Fig. 1A ). KIR2DL3 + KIR2DL1/2/S1/2 2 NK cells were sorted using a combination of KIR2DL2/3/S2-specific GL183 and KIR2DL1/S1-specific EB6 Abs from KIR2DL2/S2 2 genotyped individuals ( (Fig. 1B) . Although variable from one individual to another, the frequency of CD107a + KIR2DL2 + or CD107a + KIR2DL3 + NK cells did not correlate with the presence or absence of particular C1 or C2 alleles. Altogether, these results suggest that the stringent C2 specificity of KIR2DL1 confers an NK education only in C2 + individuals; in contrast, some HLA class I molecules previously identified as C2 ligands could be recognized by KIR2DL2 and KIR2DL3 receptors and could mediate, at least to some extent, education of KIR2DL2/3 NK cells. Thus, a preactivation of these KIR2DL NK cell subsets, notably by cytokine stimulation, seems sufficient to decrease their activation threshold.
Broad HLA-C specificity of KIR2DL2 + and KIR2DL3 + NK cells but restricted C2 specificity of KIR2DL1 + NK cells
To investigate the range of C2 specificity of KIR2DL2 and KIR2DL3, we evaluated the ability of KIR2DL NK cell subsets to recognize different C1 and C2 ligands, when compared with control KIR2DL1 + cells (Fig. 1E ). All HLA-C transfected 221 cell lines similarly expressed HLA class I molecules except 221-C*15:02, which is less recognized by KIR2DL2 and KIR2DL3 NK cells (Fig. 1F) (Fig. 2D ). In contrast, C2 2 KIR2DS1 + NK cell clones showed strong alloresponsiveness against HLA-C*04:01-and HLA-C*02:02-(C2) target cells (Fig. 2D) . The C2 specificity of KIR2DS1 was confirmed for four clones isolated from three C2 2 individuals.
Our results suggest that KIR2DS1 shows stringent C2 specificity, like its inhibitory counterpart, KIR2DL1.
C1 specificity of KIR2DS2
To address the specificity of KIR2DS2 NK cells and reassess the rules governing activation of KIR2DS2 + NK cells, we used KIR2DS2 + KIR2DL1/3/S1 2 NK cell lines from KIR2DL3 2 genotyped individuals, obtained after sorting with a combination of the KIR2DL3/S2-specific 1F12 and KIR2DL1/S1-specific EB6 Abs (20) , and subsequent in vitro expansion (Fig. 3A) . Because the KIR2DS2 + NK cell population can coexpress the inhibitory KIR2DL2, we cloned KIR2DS2 + KIR2DL1/S1 2 NK cells and discriminated KIR2DS2 + clones from KIR2DS2 2 ones by KIR2DL2
RT-PCR analysis (Fig. 3B) . (Fig. 1C) , but also the (Fig. 1) , regardless of the HLA-C background and NK cell phenotype (Fig. 4B) . The inhibitory C1-KIR2DL2 signaling bypassed the activating C1-KIR2DS2 signaling, highlighting the preponderant impact of KIR2DL2 on NK cell inhibition.
Additive effect of KIR2DL1 and KIR2DS2 against C1 + target cells
Taking into account that activation of KIR2DS2 in the presence of a C1 ligand should have an additive effect on the activation mediated by the lack of engagement of KIR2DL1, we then evaluated the impact of the coexpression of KIR2DS2 and KIR2DL1 on recognition of C1C1 + target cells. To this end, we sorted KIR2DL1 + KIR2DS2 + NK cells from KIR2DS1 and KIR2DL3 negative genotyped C2 + individuals using anti-KIR2DL3/2DS2 (1F12)-and anti-KIR2DL1/S1 (EB6)-specific Abs (Fig. 5A) . The sorted KIR2DL1 + KIR2DS2 + cells were cloned and phenotyped by KIR2DL2 RT-PCR as previously described (Fig. 3B) , to discriminate KIR2DL2 + NK cell clones. We observed a functionally additive effect of KIR2DL1 and KIR2DS2 on the recognition of the 221-HLA-C*03:04 (C1) cell line (Fig. 5B, 5C ). C2 ligands, like HLA-C*02:02 and HLA-C*04:01, engaged KIR2DL1 receptors and inhibited KIR2DS2 + KIR2DL1
+ NK cell degranulation.
The nature of KIR2D and HLA-C ligand affects the composition of the NK cell repertoire
To determine the functional impact of HLA-C-specific KIR2DL and KIR2DS receptor expression, we evaluated the phenotypic distribution of each KIR2D NK cell subset: KIR2DL1/S1 + KIR2DL2/3/ S2 2 , KIR2DL1/S1 2 KIR2DL2/3/S2 + , and KIR2DL1/S1 + KIR2DL2/ 3/S2 + NK cell subsets within KIR2DL1/2/3/S1/2 NK cells, in a cohort of 159 KIR and HLA genotyped individuals (Supplemental Table I ). Because almost all studied individuals were KIR2DL1 + genotyped (96%), this analysis was performed according to KIR2DL2, KIR2DL3, and KIR2DS2 genotype and HLA-C environment (Fig. 6A) . In this cohort, all KIR2DL2 + individuals were KIR2DS2 + genotyped; thus, we assigned the individuals in one of three groups determined by the presence of KIR2DL3, KIR2DL2/ 3/S2, and KIR2DL2/S2 genes. All studied populations were similarly represented, regardless of the HLA-C (C1C1, C1C2, or C2C2) environment (data not shown). However, KIR2DL1/S1 + KIR2DL2/3/S2 2 NK cell frequency was significantly decreased in KIR2DL2/S2 + individuals with a C2 + haplotype (Fig. 6A , Supplemental Table II ). The double-stained population frequency was not significantly different in the studied groups. The KIR2DL2/3/ S2 + KIR2DL1/S1 2 NK cell frequency was significantly higher in KIR2DL2/S2 + compared with KIR2DL3 + individuals (Fig.  6A , Supplemental Table II ) with all HLA-C molecules, and in KIR2DL2/3/S2 + compared with KIR2DL3 + individuals with C1C1 and C2C2 molecules. Finally, we analyzed the distribution of each KIR2D NK cell subset, as defined by their mean frequencies in the pool of KIR2DL1/2/3/S1/2 NK cells (Fig. 6B) , according to KIR2DL2, KIR2DL3, and KIR2DS2 genotypes and expression of either C1 or C2 molecules. The KIR2DL1/S1
+ NK cell subset predominated in KIR2DL3 + individuals, and its mean frequency increased with the number of C2 alleles (mean frequencies are 36.1, 38.4, and 47.2%, respectively, in C1C1, C1C2, and C2C2 environments). In contrast, the presence of KIR2DL2 and KIR2DS2 correlated with increased mean frequencies of KIR2DL2/3/S2 + NK cells, particularly in KIR2DL2/S2 + individuals. Although KIR2DL2 and KIR2DL3 recognized a broad spectrum of HLA-C ligands, the higher affinity of KIR2DL2 than KIR2DL3 toward HLA-C ligands could account for decreased frequency of the KIR2DL1 + NK cell pool in the former individuals. The six individuals with a KIR2DL1 Fig. 6C ), possibly as a result of compensatory KIR2DL2/S2 expression in the absence of KIR2DL1 expression. Thus, KIR2DL1 substitution by KIR2DL2 is phenotypically marked in the KIR2D repertoire and possibly allows maintenance of self C2 recognition.
Significant impact of KIR2DS1 and KIR2DS2 expression on KIR2D NK cell repertoire formation
To determine the impact of KIR2DS1 gene on the KIR2DL1/S1 NK cell compartment, we assessed the frequency of KIR2DL1 + 2DS1
2 , KIR2DL1 + 2DS1 + , and KIR2DL1 2 2DS1 + NK cell subsets (Fig.  7A) . Taking into account only the HLA-C environment, no difference in frequency was observed. However, a significantly decreased frequency of KIR2DL1 + 2DS1 2 NK cells was observed particularly in B + haplotypes regardless of the HLA-C molecules, linked directly to KIR2DS1 expression (Fig. 7A, Supplemental Table II).  The KIR2DL1 2 KIR2DS1 + NK cell subset is significantly more represented in BB than AB haplotypes because of the increased number of KIR2DS1 allele copies. KIR2DS1 expression contributed to a significantly increased KIR2DL1/S1 NK cell pool, expressed with or without KIR2DL1 on NK cells (Fig.7C, 7D) . Using a 1F12/ GL183 Ab combination (20), we investigated the frequency of KIR2DL2 + 2DL3/S2 2 and KIR2DL3/S2 + NK cell subsets according to KIR2DL2, KIR2DL3, and KIR2DS2 genes and HLA-C environment (Fig. 7B, 7E ). In accordance with the fact that KIR2DL2 and KIR2DL3 segregate as alleles (21), we observed that KIR2DL2 + KIR2DL3/S2 2 NK cell frequency is significantly higher in KIR2DL2/ S2 + than KIR2DL2/3/S2 + genotyped individuals with a C2C2 haplotype (Fig. 7B) . However, KIR2DL2 + KIR2DL3/S2 2 NK cell frequency was not twice in KIR2DL2/S2 + genotyped individuals that was observed in KIR2DL2/3/S2 + individuals with only one KIR2DL2 allele (Fig. 7E) , which suggests either coexpression of KIR2DL2 with KIR2DS2, or decreased expression of KIR2DL2. Thus, the expression of the KIR2DS1 contributes to broaden significantly the pool of KIR2DL1/S1 NK cells even though it significantly limits the KIR2DL1 + 2DS1 2 cell subset frequency. In addition, C1 reactive KIR2DS2 expression seems to function to enlarge the KIR2DL2/ 3/S2 NK cell pool, and it is conceivable that its additive effect with KIR2DL1 may contribute to limit KIR2DL1 expression on NK cells. In summary, our results suggest that together with KIR2DL2, activating KIR2DS1 and KIR2DS2 expression limits KIR2DL1 acquisition on NK cells.
Discussion
In this study, we revisited the HLA-C specificity of the main KIR2DL and determined C1 reactivity of KIR2DS2 from selected KIR2DL + or KIR2DS + NK cell lines and clones, and investigated these specificities on KIR2D NK cell formation. Our results are in accordance with numerous studies (9, 12, 13, 17, 22-28) , and notably The Journal of Immunologythose obtained by Winter et al. (13) showing that KIR2DL2 and KIR2DL3 recognize C2 allotypes using NK92 infected with Vac-KIR2DL2 or -KIR2DL3. More recently, Moesta et al. (12) have shown that KIR2DL2 is a stronger receptor for HLA-C ligand than KIR2DL3. However, among C2 allotypes, we showed that HLA-C*04:01 ligand is better recognized than the other evaluated ligands (HLA-C*02:02, -C*06:02, and -C*15:01). These results are in line with a recent observation drawn from an analysis of Table I ) and HLA-C molecules (C1C1, C1C2, and C2C2). We summed KIR2DL1/S1 + KIR2DL2/3/S2 2 , KIR2DL1/S1 2 KIR2DL2/3/S2 + , and KIR2DL1/S1 + KIR2DL2/3/S2 + NK cell subsets, weighting them according to their frequency indicated in the pie chart. The size of the pie chart is proportional to the frequency of KIR2D NK cells (KIR2DL1/2/3/2DS1/2), and it is indicated (6SD) in the bottom left of each group in italics. The number of studied individuals in each group is indicated in the bottom right. (C) Scatter plots represent KIR2DL2/3/2DS2 + NK cell frequency in KIR2DL1 2 (n = 6) and KIR2DL1 + (n = 13) genotyped individuals. The mean frequency is indicated in each group by a black feature. Individuals have been identified following KIR2DS1 genotype and HLA-C molecules (C1C1, C1C2, and C2C2). Statistical significance (*p , 0.05, **p # 0.001) between two groups was determined using the one-way ANOVA test (Supplemental Table II) . a large panel of single-HLA class I molecule beads based on Luminex, which showed a broader pattern of HLA-C recognition by KIR2DL2-Fc fusion protein, even using unloaded HLA class I molecules (12) . Recently, we have shown that KIR2DL3 + NK cell lines equally recognized either C1C1 or C2C2 immature dendritic cells (29) . The low affinity of the KIR2DL2/3 to HLA-C ligand is likely reinforced and stabilized within the immune synapse by other receptor-ligand interactions, thus allowing functional KIR-HLA interactions. Besides the wide spectrum of HLA-C recognition by KIR2DL2 and KIR2DL3, another important message of our study is the ability of activated KIR2DL2 + and KIR2DL3 + NK cells to recognize the "missing-self" irrespective of their HLA-C background. Our results are in agreement with those of Anfossi et al. (7), who suggested education of KIR2DL3 + NK cells mainly from a C1 + environment. Indeed, we observed that resting C1 2 KIR2DL3 + NK cells are less receptive to missing-self activation (data not shown); however, KIR2DL3 engagement with C2 ligands during NK development or cytokine stimulation could enhance the response to missing-self after a preactivation, resulting in a decrease of their activation threshold. This point is essential in particular pathological contexts, such as viral infection, tumor processes, and HSCT, where activation could increase the missingself response of poorly educated cells such as C1 2 KIR2DL3 + NK cells or KIR2DL2 + NK cells. In contrast with other approaches based on soluble KIR-Ig proteins, KIR2D transfected cells, or a vaccinia expression system, our results were drawn from NK cells purified from different individuals with a physiological KIR2D expression. The more sensitive cellular model probably allows assessment of low-avidity interactions between of KIR2D and HLA-C, which could explain discordant results with those obtained with binding assays using KIR2D-Ig fusion proteins (13) . This is typically the case for soluble KIR2DS receptors, which did not bind to any of the HLA class I molecules expressed on a large panel of transfected cells (13) . In our cellular model, we showed that KIR2DS2 recognizes only C1 ligands, in contrast with its inhibitory KIR2DL2 form, in Table I + ) and HLA-C molecules (C1C1, C1C2, and C2C2). We summed KIR2DL2 + 2DL3/S2 2 and KIR2DL2 2 2DL3/S2 + NK cell subsets, weighting them according to their frequency indicated in the pie chart. The size of the pie chart is proportional to the frequency of KIR NK cell pool and it is indicated (6SD) in the bottom left of each group in italics. The number of studied individuals in each group is indicated in the bottom right. Statistical significance (*p , 0.05, **p # 0.001) between two groups was determined using the one-way ANOVA test (Supplemental Table II ).
all HLA-C environments. Failed C1/KIR2DS2 interactions using soluble KIR2DS2-Ig fusion proteins or KIR2DS2 tetramers (30) would suggest weak affinities. Thus, the few substitutions between the extracellular parts of both receptors could explain these apparent discrepancies. KIR2DS1 and KIR2DS2 show a lower affinity than their inhibitory counterparts with overlapping specificity, ensuring that inhibition signals override activation signals. However, in the absence of inhibitory KIR signals, the engagement of activating KIR2DS is sufficient to trigger NK cell responses.
The broader specificity of KIR2DL2 and KIR2DL3 toward HLA-C alleles also recognized by KIR2DL1 would explain the predominant expression of this compartment within the KIR2D NK cell repertoire. KIR2DL1 is predominantly represented in a C2C2 environment in the presence of KIR2DL3, but its representation is decreased in the presence of KIR2DL2 and KIR2DS2 genes. One possible explanation for this is that KIR2DL2 is a stronger competitor than KIR2DL3 for C2 ligands, explaining its predominant representation in the KIR2D NK cell pool in a C2C2 environment. Moreover, the high proportion of KIR2DS1 + NK cells in the KIR2DL1/S1 pool could contribute to the decreased frequency of KIR2DL1 + 2DS1 2 NK cells. Thus, all inhibitory and activating KIR2D are functional, but the strength of HLA-C affinity is different, ensuring a hierarchy between these KIR2D, and explains, in part, the formation of the NK cell repertoire depending on the HLA-C environment. In this regard, we observed in KIR2DL1 2 genotyped individuals that KIR2DL2/3/2DS2 expression was significantly increased compared with KIR2DL1 + genotyped counterparts, suggesting an adjustment of the KIR2D repertoire formation after the distribution of each pool. This observation may not be compatible with a sequential acquisition of KIR with KIR2DL1 expression after KIR2DL2 and KIR2DL3 as proposed by Uhrberg's group (9) . It is likely that the adjustment is more continuous and that the KIR2D expression can be readjusted according to other KIR2D expressed, as previously proposed (10) .
The C2-expressing fetuses carried by group A KIR homozygous mothers constitute a risk factor for pre-eclampsia (31) and recurrent miscarriage (32) during pregnancy. In contrast, fetal C1 homozygosity and maternal group B KIR haplotype are protective (31, 32) . Thus, it is conceivable that strong inhibitory KIR2DL2 maintains proper inhibition of NK cell responses against C1 fetal cells, whereas the weak inhibitor KIR2DL3, which is potentially efficient in C2 individuals on activated NK cells, may not properly inhibit NK cell response against allogeneic C2 ligands, resulting in pre-eclampsia or miscarriage. Moreover, although KIR2DL2 and KIR2DL3 segregate as alleles, only KIR2DL3 was associated with resistance to hepatitis C virus (33) . The weaker interaction between KIR2DL3 and C1 ligand could be reinforced by particular peptides of viral or endogenous origin (34) . In an HSCT context, it has been documented that KIR2DL2/3 and KIR2DS2 are predominantly expressed during hematopoietic reconstitution (35) . In this activated context, KIR2DL2 + and KIR2DL3 + NK cells from C2C2 donors should ensure the missing-self recognition to compensate the default of functional KIR2DL1 + NK cell recovery. A previous study has defined five types of NK cell repertoire based on KIR dominant or NKG2A dominant expression, receptornull expression, single-receptor expression, KIR-KIR coexpression, and NKG2A-KIR coexpression, and revealed a balance of KIR/ NKG2A (36) . This study was performed mainly from AA haplotype individuals and it would be interesting to investigate these types of repertoires taking into account the presence or absence of KIR2DL2/S2 and KIR2DS1 genes. Moreover, different affinities for the same HLA-C ligand have been shown for different KIR2DL3 allele products (12, 17) , and this affinity can be modulated by the nature of loaded peptide (23) . Thus, the formation of the KIR2D NK repertoire is probably finely adjusted depending on the KIR2DL polymorphism and on the other NK cell subsets. In this regard, we have recently shown the impact of KIR3DL1 allelic nature on KIR3DL1 NK repertoire formation (37) . These recent investigations suggest primary expression of KIR3DL1 followed by KIR2D acquisition. The impact of allelic KIR3DL1 and a Bw4 environment on KIR2D NK cell repertoire should be studied in a larger cohort. Altogether, our results suggest that the nature of the HLA-C-specific activating and inhibitory KIR2D expressed and the ligand environment directs the structure of NK cell repertoire.
